Insulet (Nasdaq:PODD) shares got a boost before the market opened today on fourth-quarter results that came in ahead of the consensus forecast.
Shares of PODD ticked up 3.5% to $255.02 apiece in pre-market trading today.
The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $101.6 million. That equals $1.44 per share on sales of $783.8 million for the three months ended Dec. 31, 2025.
Insulet recorded a 0.9% bottom-line gain on a sales increase of 31.2%.
Adjusted to exclude one-time items, earnings per share came in at $1.55. That landed 9¢ ahead of expectations on Wall Street. Sales topped the forecast, too, as experts projected $768.7 million in revenue.
In the quarter, total Omnipod revenue reached $2.7 billion, marking a rise of 31.6%. The company also said it ranked first in new customer starts in both the U.S. and Europe in 2025, achieving record new customer starts in Q4 and for the full year.
President and CEO Ashley McEvoy outlined some of the future plans for Omnipod in an interview with Drug Delivery Business News last fall, while she and other Insulet leaders expanded on those plans during the company’s November Investor Day event. Those plans include next-generation platforms and algorithms, among other advancements.
Insulet did not provide specific figures on its 2026 guidance but anticipates sales growth between 20% and 22% and adjusted EPS growth greater than 25% year-over-year.
https://www.drugdeliverybusiness.com/insulet-q4-2025-beats-stock-growth/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.